首页 > 最新文献

Pain Practice最新文献

英文 中文
Elevated lead impedances in spinal cord stimulation systems 脊髓刺激系统的导联阻抗升高
IF 2.6 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-09-13 DOI: 10.1111/papr.13415
Alaa Abd‐Elsayed, Christopher Gilligan
{"title":"Elevated lead impedances in spinal cord stimulation systems","authors":"Alaa Abd‐Elsayed, Christopher Gilligan","doi":"10.1111/papr.13415","DOIUrl":"https://doi.org/10.1111/papr.13415","url":null,"abstract":"","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":"20 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142268625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low‐energy differential target multiplexed SCS derivative reduces pain and improves quality of life through 12 months in patients with chronic back and/or leg pain 低能量差分靶向多路复用体外脊髓刺激疗法衍生物可在 12 个月内减轻慢性背痛和/或腿痛患者的疼痛并改善其生活质量
IF 2.6 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-09-11 DOI: 10.1111/papr.13407
Jeffery Peacock, David Provenzano, Michael Fishman, Kasra Amirdelfan, Todd Bromberg, Todd Schmidt, Thomas White, Prabhdeep Grewal, Rafael Justiz, Aaron Calodney, Amr El‐Naggar, Binit Shah, Michael Esposito, Kliment Gatzinsky, Jan Willem Kallewaard, Lawrence Poree, Andrew Cleland, Calysta Rice, Erin Theis, Kate Noel, Maddie LaRue
IntroductionEnergy‐reducing spinal cord stimulation (SCS) approaches have the potential to impact patient experience with rechargeable and non‐rechargeable SCS devices through reducing device recharge time or enhancing device longevity. This prospective, multi‐center study evaluated the safety, effectiveness, and actual energy usage of differential target multiplexed (DTM) endurance therapy, a reduced energy DTM SCS derivative.MethodsSubjects who reported an overall pain visual analog score (VAS) of ≥6/10 cm and an Oswestry Disability Index score of 21–80 out of 100 at baseline with moderate to severe chronic, intractable back and/or leg pain were eligible. Evaluation visits occurred at 1, 3, 6, and 12 months post‐device activation. The primary objective was to characterize change in overall pain intensity, as measured by VAS, from baseline to 3‐month visit.ResultsFifty‐seven subjects enrolled at 12 US sites from November 2020 through June 2021, 35 were implanted with a rechargeable SCS device, and 27 completed the 12‐month visit. Subjects experienced a 50.4% mean reduction in overall pain from baseline at the 3‐month follow‐up that was sustained through 12 months. Additional outcomes including changes in overall, back, and leg pain intensity, quality of life, disability, therapy satisfaction, safety, and current battery usage are shown through 12‐month follow‐up.ConclusionThe use of DTM endurance SCS therapy in this study resulted in reductions in pain relief through 12 months, demonstrating that energy‐reducing stimulation patterns can provide clinical benefit. Clinically effective, reduced energy SCS derivatives have the potential to impact patient experience through either reduced recharge requirements or increased device longevity.
导言减少能量的脊髓刺激(SCS)方法有可能通过减少设备充电时间或延长设备寿命来影响患者使用可充电和不可充电 SCS 设备的体验。这项前瞻性多中心研究评估了差分靶向多路复用(DTM)耐力疗法(一种降低能量的 DTM SCS 衍生物)的安全性、有效性和实际能量使用情况。方法基线时报告总体疼痛视觉模拟评分(VAS)≥6/10 厘米、Oswestry 残疾指数评分(满分 100 分,21-80 分)为中度至重度慢性顽固性背部和/或腿部疼痛的受试者均符合条件。评估访问在设备激活后的 1、3、6 和 12 个月进行。结果2020 年 11 月至 2021 年 6 月期间,57 名受试者在美国的 12 个地点注册,35 名受试者植入了可充电 SCS 装置,27 名受试者完成了 12 个月的访问。在 3 个月的随访中,受试者的总体疼痛平均比基线减轻了 50.4%,并持续了 12 个月。其他结果包括总体、背部和腿部疼痛强度、生活质量、残疾程度、治疗满意度、安全性和当前电池使用情况的变化,这些结果都显示在 12 个月的随访中。临床有效的减能量 SCS 衍生物有可能通过降低充电要求或延长设备寿命来影响患者的体验。
{"title":"Low‐energy differential target multiplexed SCS derivative reduces pain and improves quality of life through 12 months in patients with chronic back and/or leg pain","authors":"Jeffery Peacock, David Provenzano, Michael Fishman, Kasra Amirdelfan, Todd Bromberg, Todd Schmidt, Thomas White, Prabhdeep Grewal, Rafael Justiz, Aaron Calodney, Amr El‐Naggar, Binit Shah, Michael Esposito, Kliment Gatzinsky, Jan Willem Kallewaard, Lawrence Poree, Andrew Cleland, Calysta Rice, Erin Theis, Kate Noel, Maddie LaRue","doi":"10.1111/papr.13407","DOIUrl":"https://doi.org/10.1111/papr.13407","url":null,"abstract":"IntroductionEnergy‐reducing spinal cord stimulation (SCS) approaches have the potential to impact patient experience with rechargeable and non‐rechargeable SCS devices through reducing device recharge time or enhancing device longevity. This prospective, multi‐center study evaluated the safety, effectiveness, and actual energy usage of differential target multiplexed (DTM) endurance therapy, a reduced energy DTM SCS derivative.MethodsSubjects who reported an overall pain visual analog score (VAS) of ≥6/10 cm and an Oswestry Disability Index score of 21–80 out of 100 at baseline with moderate to severe chronic, intractable back and/or leg pain were eligible. Evaluation visits occurred at 1, 3, 6, and 12 months post‐device activation. The primary objective was to characterize change in overall pain intensity, as measured by VAS, from baseline to 3‐month visit.ResultsFifty‐seven subjects enrolled at 12 US sites from November 2020 through June 2021, 35 were implanted with a rechargeable SCS device, and 27 completed the 12‐month visit. Subjects experienced a 50.4% mean reduction in overall pain from baseline at the 3‐month follow‐up that was sustained through 12 months. Additional outcomes including changes in overall, back, and leg pain intensity, quality of life, disability, therapy satisfaction, safety, and current battery usage are shown through 12‐month follow‐up.ConclusionThe use of DTM endurance SCS therapy in this study resulted in reductions in pain relief through 12 months, demonstrating that energy‐reducing stimulation patterns can provide clinical benefit. Clinically effective, reduced energy SCS derivatives have the potential to impact patient experience through either reduced recharge requirements or increased device longevity.","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":"390 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142185066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
10. Complex regional pain syndrome 10.复杂区域疼痛综合征
IF 2.6 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-09-11 DOI: 10.1111/papr.13413
Daniël P. C. van der Spek, Maaike Dirckx, Thomas J. P. Mangnus, Steven P. Cohen, Frank J. P. M. Huygen
IntroductionComplex regional pain syndrome (CRPS) is a clinical disorder that can develop following surgery or trauma. Based on the most prominent underlying pathophysiological mechanisms, CRPS can be classified into different subtypes, namely inflammatory, nociplastic/neuropathic, vasomotor, and motor. Depending on the subtype, personalized treatment can be applied. If conservative treatments are insufficient or ineffective, more invasive treatments may be recommended. This article provides an overview of the most recent insights into CRPS and discusses the most common invasive treatments.MethodsThe literature regarding interventional treatments for CRPS has been systematically reviewed and summarized.ResultsBisphosphonates are effective in treating the inflammatory subtype, while ketamine can provide pain relief for the nociplastic/neuropathic subtype. Sympathetic blocks are effective in addressing vasomotor disturbances. For patients with refractory symptoms, neurostimulation is a viable option due to its multimechanistic properties for all subtypes. End‐of‐line motor disturbances may benefit from intrathecal baclofen.ConclusionsCRPS is a debilitating condition with an unpredictable course. The effectiveness of treatment varies from patient to patient. When conservative approaches prove insufficient, gradual progression to invasive treatments based on the underlying subtype is recommended.
导言 复杂区域性疼痛综合征(CRPS)是一种临床疾病,可在手术或创伤后发生。根据最突出的潜在病理生理机制,CRPS 可分为不同的亚型,即炎症型、神经痉挛/神经病理性型、血管运动型和运动型。根据亚型的不同,可以采用个性化的治疗方法。如果保守治疗不足或无效,可能会建议采用更具侵入性的治疗方法。本文概述了对CRPS的最新见解,并讨论了最常见的侵入性治疗方法。结果双膦酸盐可有效治疗炎症亚型,而氯胺酮可缓解非痉挛性/神经病理性亚型的疼痛。交感神经阻滞可有效解决血管运动障碍。对于有难治性症状的患者,神经刺激是一种可行的选择,因为它具有针对所有亚型的多机制特性。结论 CRPS 是一种使人衰弱的疾病,病程难以预测。治疗效果因人而异。当保守治疗效果不佳时,建议根据潜在的亚型逐步过渡到侵入性治疗。
{"title":"10. Complex regional pain syndrome","authors":"Daniël P. C. van der Spek, Maaike Dirckx, Thomas J. P. Mangnus, Steven P. Cohen, Frank J. P. M. Huygen","doi":"10.1111/papr.13413","DOIUrl":"https://doi.org/10.1111/papr.13413","url":null,"abstract":"IntroductionComplex regional pain syndrome (CRPS) is a clinical disorder that can develop following surgery or trauma. Based on the most prominent underlying pathophysiological mechanisms, CRPS can be classified into different subtypes, namely inflammatory, nociplastic/neuropathic, vasomotor, and motor. Depending on the subtype, personalized treatment can be applied. If conservative treatments are insufficient or ineffective, more invasive treatments may be recommended. This article provides an overview of the most recent insights into CRPS and discusses the most common invasive treatments.MethodsThe literature regarding interventional treatments for CRPS has been systematically reviewed and summarized.ResultsBisphosphonates are effective in treating the inflammatory subtype, while ketamine can provide pain relief for the nociplastic/neuropathic subtype. Sympathetic blocks are effective in addressing vasomotor disturbances. For patients with refractory symptoms, neurostimulation is a viable option due to its multimechanistic properties for all subtypes. End‐of‐line motor disturbances may benefit from intrathecal baclofen.ConclusionsCRPS is a debilitating condition with an unpredictable course. The effectiveness of treatment varies from patient to patient. When conservative approaches prove insufficient, gradual progression to invasive treatments based on the underlying subtype is recommended.","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":"19 1","pages":""},"PeriodicalIF":2.6,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142185065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Smaller thoracic canal diameters are associated with thoracic radiculopathy and abdominal pain after spinal cord stimulator paddle lead placement. 较小的胸椎管直径与脊髓刺激器桨状导联线置入后的胸椎根性病变和腹痛有关。
IF 2.5 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-09-06 DOI: 10.1111/papr.13414
Brian T Ragel, Matthew McGehee, Nicolas Karvelas, Ahmed M Raslan

Introduction: It is not uncommon for patients to experience postoperative neurologic deficit, thoracic radiculopathy, abdominal pain, or lower extremity paresthesia after the implantation of thoracic spinal cord stimulator (SCS) paddle leads. Smaller thoracic canal diameters have previously been associated with postoperative neurologic deficits.

Objective: This imaging study examined whether postoperative SCS neurologic complaints other than neurologic deficit may be correlated with thoracic spinal canal diameter.

Methods: Patients who underwent thoracic laminotomy for SCS paddle lead placement between January 2018 and March 2023 were identified. Preoperative thoracic canal diameter was measured on MRI or CT imaging in the sagittal plane from T5/6 to T11/12. The canal diameters of patients with and without new postoperative neurologic complaints were compared.

Results: Two hundred forty-six patients underwent thoracic laminotomy for SCS paddle lead placement. Thoracic radiculopathy, abdominal pain, and lower extremity paresthesia occurred in 3.7% (9/246), 2.8% (7/246), and 2.0% (5/246) patients, respectively. The mean canal diameter for patients without neurologic complaint, thoracic radiculopathy, abdominal pain, and lower extremity paresthesia was 13.1 mm, 12.0 mm (p < 0.0001), 12.1 mm (p < 0.01), and 12.8 mm (p = 0.365), respectively.

Conclusion: A smaller thoracic canal diameter is associated with postoperative thoracic radiculopathy and abdominal pain. We believe that surgical planning to create adequate space for SCS leads is critical in preventing postoperative neurologic complaints of deficit, thoracic radiculopathy, and abdominal pain.

导言:植入胸椎脊髓刺激器(SCS)桨状导线后,患者术后出现神经功能缺损、胸椎根性病变、腹痛或下肢麻痹的情况并不少见。较小的胸椎管直径曾与术后神经功能缺损有关:本影像学研究探讨了 SCS 术后除神经功能缺损外的其他神经症状是否与胸椎管直径相关:确定了 2018 年 1 月至 2023 年 3 月间因 SCS 桨状导联置入而接受胸椎椎板切开术的患者。术前胸椎管直径通过 MRI 或 CT 成像在 T5/6 至 T11/12 的矢状面上进行测量。对术后出现和未出现新的神经系统症状的患者的胸椎管直径进行比较:结果:246 名患者接受了胸椎椎板切除术,以植入 SCS 桨状导联。分别有 3.7%(9/246)、2.8%(7/246)和 2.0%(5/246)的患者出现胸椎根性病变、腹痛和下肢麻痹。无神经系统主诉、胸椎根性病变、腹痛和下肢麻痹的患者的胸椎管平均直径分别为 13.1 毫米、12.0 毫米(p 结论:胸椎管直径越小,下肢麻痹越严重:较小的胸椎管直径与术后胸椎根性病变和腹痛有关。我们认为,为 SCS 导联创造足够空间的手术规划对于预防术后神经功能缺损、胸椎根性病变和腹痛等症状至关重要。
{"title":"Smaller thoracic canal diameters are associated with thoracic radiculopathy and abdominal pain after spinal cord stimulator paddle lead placement.","authors":"Brian T Ragel, Matthew McGehee, Nicolas Karvelas, Ahmed M Raslan","doi":"10.1111/papr.13414","DOIUrl":"https://doi.org/10.1111/papr.13414","url":null,"abstract":"<p><strong>Introduction: </strong>It is not uncommon for patients to experience postoperative neurologic deficit, thoracic radiculopathy, abdominal pain, or lower extremity paresthesia after the implantation of thoracic spinal cord stimulator (SCS) paddle leads. Smaller thoracic canal diameters have previously been associated with postoperative neurologic deficits.</p><p><strong>Objective: </strong>This imaging study examined whether postoperative SCS neurologic complaints other than neurologic deficit may be correlated with thoracic spinal canal diameter.</p><p><strong>Methods: </strong>Patients who underwent thoracic laminotomy for SCS paddle lead placement between January 2018 and March 2023 were identified. Preoperative thoracic canal diameter was measured on MRI or CT imaging in the sagittal plane from T5/6 to T11/12. The canal diameters of patients with and without new postoperative neurologic complaints were compared.</p><p><strong>Results: </strong>Two hundred forty-six patients underwent thoracic laminotomy for SCS paddle lead placement. Thoracic radiculopathy, abdominal pain, and lower extremity paresthesia occurred in 3.7% (9/246), 2.8% (7/246), and 2.0% (5/246) patients, respectively. The mean canal diameter for patients without neurologic complaint, thoracic radiculopathy, abdominal pain, and lower extremity paresthesia was 13.1 mm, 12.0 mm (p < 0.0001), 12.1 mm (p < 0.01), and 12.8 mm (p = 0.365), respectively.</p><p><strong>Conclusion: </strong>A smaller thoracic canal diameter is associated with postoperative thoracic radiculopathy and abdominal pain. We believe that surgical planning to create adequate space for SCS leads is critical in preventing postoperative neurologic complaints of deficit, thoracic radiculopathy, and abdominal pain.</p>","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142140776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter to the editor on "The effect of ketamine on acute and chronic wound pain in patients undergoing breast surgery: A meta-analysis and systematic review". 致编辑的信,主题为 "氯胺酮对乳房手术患者急性和慢性伤口疼痛的影响:荟萃分析和系统综述"。
IF 2.5 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-09-01 Epub Date: 2024-03-28 DOI: 10.1111/papr.13374
Umar Akram, Zain Ali Nadeem
{"title":"Letter to the editor on \"The effect of ketamine on acute and chronic wound pain in patients undergoing breast surgery: A meta-analysis and systematic review\".","authors":"Umar Akram, Zain Ali Nadeem","doi":"10.1111/papr.13374","DOIUrl":"10.1111/papr.13374","url":null,"abstract":"","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":" ","pages":"965"},"PeriodicalIF":2.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140306436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The current state of training in pain medicine fellowships: An Association of Pain Program Directors (APPD) survey of program directors. 疼痛医学研究员培训的现状:疼痛项目主任协会 (APPD) 对项目主任的调查。
IF 2.5 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-09-01 Epub Date: 2024-03-30 DOI: 10.1111/papr.13373
Sayed Emal Wahezi, Trent D Emerick, Moorice Caparó, Heejung Choi, Yashar Eshraghi, Tahereh Naeimi, Lynn Kohan, Magdalena Anitescu, Thelma Wright, Rene Przkora, Kiran Patel, Tim J Lamer, Susan Moeschler, Ugur Yener, Jonathan Alerte, Radhika Grandhe, Alexander Bautista, Boris Spektor, Kristen Noon, Rajiv Reddy, Uzondu C Osuagwu, Anna Carpenter, Frederic J Gerges, Danielle B Horn, Casey A Murphy, Chong Kim, Scott G Pritzlaff, Cameron Marshall, Gwynne Kirchen, Christine Oryhan, Tejinder S Swaran Singh, Dawood Sayed, Timothy R Lubenow, Nalini Sehgal, Charles E Argoff, Amit Gulati, Miles R Day, Naum Shaparin, Nabil Sibai, Anterpreet Dua, Meredith Barad

Introduction: The Accreditation Council for Graduate Medical Education (ACGME) approved the first pain medicine fellowship programs over three decades ago, designed around a pharmacological philosophy. Following that, there has been a rise in the transition of pain medicine education toward a multidisciplinary interventional model based on a tremendous surge of contemporaneous literature in these areas. This trend has created variability in clinical experience and education amongst accredited pain medicine programs with minimal literature evaluating the differences and commonalities in education and experience of different pain medicine fellowships through Program Director (PD) experiences. This study aims to gather insight from pain medicine fellowship program directors across the country to assess clinical and interventional training, providing valuable perspectives on the future of pain medicine education.

Methods: This study involved 56 PDs of ACGME-accredited pain fellowship programs in the United States. The recruitment process included three phases: advanced notification, invitation, and follow-up to maximize response rate. Participants completed a standard online questionnaire, covering various topics such as subcategory fields, online platforms for supplemental education, clinical experience, postgraduate practice success, and training adequacy.

Results: Surveys were completed by 39/56 (69%) standing members of the Association of Pain Program Directors (APPD). All PDs allowed fellows to participate in industry-related and professional society-related procedural workshops, with 59% encouraging these workshops. PDs emphasized the importance of integrity, professionalism, and diligence for long-term success. Fifty-four percent of PDs expressed the need for extension of fellowship training to avoid supplemental education by industry or pain/spine societies.

Conclusion: This study highlights the challenge of providing adequate training in all Pain Medicine subtopics within a 12-month pain medicine fellowship. PDs suggest the need for additional training for fellows and discuss the importance of curriculum standardization.

简介:三十多年前,美国毕业医学教育认证委员会(ACGME)批准了第一批疼痛医学奖学金项目,这些项目是围绕药理学理念设计的。此后,基于这些领域大量同期文献的涌现,疼痛医学教育开始向多学科介入模式过渡。这一趋势造成了经认证的疼痛医学项目在临床经验和教育方面的差异,而通过项目主任(PD)的经验来评估不同疼痛医学奖学金在教育和经验方面的差异和共性的文献却少之又少。本研究旨在收集全国各地疼痛医学奖学金项目主任的见解,以评估临床和介入培训,为疼痛医学教育的未来提供有价值的观点:本研究涉及美国经 ACGME 认证的疼痛研究项目的 56 名项目主任。招募过程包括三个阶段:提前通知、邀请和后续跟踪,以最大限度地提高回复率。参与者填写了一份标准的在线问卷,内容涉及子类别领域、补充教育在线平台、临床经验、研究生实践成功率和培训充分性等多个主题:疼痛项目主任协会(APPD)的39/56(69%)名长期会员完成了调查。所有项目主任都允许学员参加行业相关和专业协会相关的程序研讨会,其中59%的项目主任鼓励学员参加这些研讨会。项目主任强调了诚信、专业和勤奋对长期成功的重要性。54%的专业医师表示有必要扩大研究员培训,以避免行业或疼痛/脊柱学会的补充教育:本研究强调了在为期 12 个月的疼痛医学研究金中提供所有疼痛医学子课题的充分培训所面临的挑战。专业医师建议需要对研究员进行额外培训,并讨论了课程标准化的重要性。
{"title":"The current state of training in pain medicine fellowships: An Association of Pain Program Directors (APPD) survey of program directors.","authors":"Sayed Emal Wahezi, Trent D Emerick, Moorice Caparó, Heejung Choi, Yashar Eshraghi, Tahereh Naeimi, Lynn Kohan, Magdalena Anitescu, Thelma Wright, Rene Przkora, Kiran Patel, Tim J Lamer, Susan Moeschler, Ugur Yener, Jonathan Alerte, Radhika Grandhe, Alexander Bautista, Boris Spektor, Kristen Noon, Rajiv Reddy, Uzondu C Osuagwu, Anna Carpenter, Frederic J Gerges, Danielle B Horn, Casey A Murphy, Chong Kim, Scott G Pritzlaff, Cameron Marshall, Gwynne Kirchen, Christine Oryhan, Tejinder S Swaran Singh, Dawood Sayed, Timothy R Lubenow, Nalini Sehgal, Charles E Argoff, Amit Gulati, Miles R Day, Naum Shaparin, Nabil Sibai, Anterpreet Dua, Meredith Barad","doi":"10.1111/papr.13373","DOIUrl":"10.1111/papr.13373","url":null,"abstract":"<p><strong>Introduction: </strong>The Accreditation Council for Graduate Medical Education (ACGME) approved the first pain medicine fellowship programs over three decades ago, designed around a pharmacological philosophy. Following that, there has been a rise in the transition of pain medicine education toward a multidisciplinary interventional model based on a tremendous surge of contemporaneous literature in these areas. This trend has created variability in clinical experience and education amongst accredited pain medicine programs with minimal literature evaluating the differences and commonalities in education and experience of different pain medicine fellowships through Program Director (PD) experiences. This study aims to gather insight from pain medicine fellowship program directors across the country to assess clinical and interventional training, providing valuable perspectives on the future of pain medicine education.</p><p><strong>Methods: </strong>This study involved 56 PDs of ACGME-accredited pain fellowship programs in the United States. The recruitment process included three phases: advanced notification, invitation, and follow-up to maximize response rate. Participants completed a standard online questionnaire, covering various topics such as subcategory fields, online platforms for supplemental education, clinical experience, postgraduate practice success, and training adequacy.</p><p><strong>Results: </strong>Surveys were completed by 39/56 (69%) standing members of the Association of Pain Program Directors (APPD). All PDs allowed fellows to participate in industry-related and professional society-related procedural workshops, with 59% encouraging these workshops. PDs emphasized the importance of integrity, professionalism, and diligence for long-term success. Fifty-four percent of PDs expressed the need for extension of fellowship training to avoid supplemental education by industry or pain/spine societies.</p><p><strong>Conclusion: </strong>This study highlights the challenge of providing adequate training in all Pain Medicine subtopics within a 12-month pain medicine fellowship. PDs suggest the need for additional training for fellows and discuss the importance of curriculum standardization.</p>","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":" ","pages":"895-903"},"PeriodicalIF":2.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140326930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lacertus notch as a sign of lacertus syndrome. 作为拉克特综合征标志的拉克特凹痕。
IF 2.5 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-09-01 Epub Date: 2024-03-29 DOI: 10.1111/papr.13372
Jean-Paul Brutus, Thiên-Trang Vo, Min Cheol Chang

Objective: Many clinicians are unfamiliar with a diagnosis of lacertus syndrome (LS). We investigated the value of the lacertus notch sign in diagnosing LS.

Methods: We included 56 consecutive patients (112 upper extremities) who had neuropathic pain and neurological symptoms of the hand. The presence of LS and the lacertus notch sign in each upper extremity was assessed.

Results: Of the 83 upper extremities with LS, 54 (65.1%) had a lacertus notch sign, whereas 29 (34.9%) did not. Of the 29 upper extremities without LS, 9 (31.0%) and 20 (69.0%) had and did not have a lacertus notch sign, respectively. The rates of lacertus notch presence in upper extremities with and without LS were significantly different. Of the 63 upper extremities with a lacertus notch sign, 54 (85.7%) were diagnosed with LS, whereas 9 (14.3%) were not. Of the 49 upper extremities without a lacertus notch sign, 20 (40.8%) were diagnosed with LS, and 29 (59.2%) were not. We observed significant differences in the rates of LS in upper extremities with and without lacertus notch.

Conclusions: The presence of the lacertus notch sign is useful for diagnosing LS. When patients with neuropathic pain and neurological symptoms present with a lacertus notch sign, clinicians should consider the possibility of LS.

目的:许多临床医生对腔隙综合征(LS)的诊断并不熟悉。我们研究了拉克图斯切迹征在诊断拉克图斯综合征中的价值:我们连续收治了 56 名手部有神经病理性疼痛和神经症状的患者(112 名上肢患者)。方法:我们连续纳入了 56 例(112 只上肢)手部神经痛和神经症状患者,评估了每只上肢是否存在 LS 和裂隙征:结果:在 83 个有 LS 的上肢中,54 个(65.1%)有拉克尔特切迹,29 个(34.9%)没有。在 29 例未出现 LS 的上肢中,分别有 9 例(31.0%)和 20 例(69.0%)出现和未出现裂隙切迹。有LS和没有LS的上肢中,出现裂隙切迹的比例有显著差异。在63例有裂隙切迹的上肢中,54例(85.7%)被诊断为LS,9例(14.3%)未被诊断为LS。在 49 例无腔隙切迹的上肢中,20 例(40.8%)被诊断为 LS,29 例(59.2%)未被诊断为 LS。我们观察到,在有和无腔隙切迹的上肢中,LS的发病率存在明显差异:结论:腔隙切迹的存在有助于诊断 LS。当神经病理性疼痛和神经症状患者出现裂隙切迹时,临床医生应考虑 LS 的可能性。
{"title":"Lacertus notch as a sign of lacertus syndrome.","authors":"Jean-Paul Brutus, Thiên-Trang Vo, Min Cheol Chang","doi":"10.1111/papr.13372","DOIUrl":"10.1111/papr.13372","url":null,"abstract":"<p><strong>Objective: </strong>Many clinicians are unfamiliar with a diagnosis of lacertus syndrome (LS). We investigated the value of the lacertus notch sign in diagnosing LS.</p><p><strong>Methods: </strong>We included 56 consecutive patients (112 upper extremities) who had neuropathic pain and neurological symptoms of the hand. The presence of LS and the lacertus notch sign in each upper extremity was assessed.</p><p><strong>Results: </strong>Of the 83 upper extremities with LS, 54 (65.1%) had a lacertus notch sign, whereas 29 (34.9%) did not. Of the 29 upper extremities without LS, 9 (31.0%) and 20 (69.0%) had and did not have a lacertus notch sign, respectively. The rates of lacertus notch presence in upper extremities with and without LS were significantly different. Of the 63 upper extremities with a lacertus notch sign, 54 (85.7%) were diagnosed with LS, whereas 9 (14.3%) were not. Of the 49 upper extremities without a lacertus notch sign, 20 (40.8%) were diagnosed with LS, and 29 (59.2%) were not. We observed significant differences in the rates of LS in upper extremities with and without lacertus notch.</p><p><strong>Conclusions: </strong>The presence of the lacertus notch sign is useful for diagnosing LS. When patients with neuropathic pain and neurological symptoms present with a lacertus notch sign, clinicians should consider the possibility of LS.</p>","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":" ","pages":"891-894"},"PeriodicalIF":2.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140326929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Corrigendum. 更正。
IF 2.5 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-09-01 Epub Date: 2024-04-21 DOI: 10.1111/papr.13376
Eugene R Viscusi
{"title":"Corrigendum.","authors":"Eugene R Viscusi","doi":"10.1111/papr.13376","DOIUrl":"10.1111/papr.13376","url":null,"abstract":"","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":" ","pages":"969-970"},"PeriodicalIF":2.5,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11717570/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140865099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pudendal nerve blockade for persistent genital arousal disorder (PGAD): A clinical review and case report. 阴部神经阻滞治疗持续性生殖器唤起障碍(PGAD):临床回顾与病例报告。
IF 2.5 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-07-01 Epub Date: 2024-03-10 DOI: 10.1111/papr.13362
Michael J Gyorfi, Alaa Abd-Elsayed

Background: Persistent genital arousal disorder (PGAD) is a condition characterized by unwanted and potentially painful genital sensations or spontaneous orgasms without stimulation. We present a case of a 55-year-old woman with refractory genital arousal disorder that was treated with serial pudendal nerve blocks.

Case: RW is a 55-year-old woman with chronic pelvic pain, pudendal neuralgia, MDD, SI, GAD, CRPS, and persistent genital arousal disorder for 11 years. Her PGAD was refractory to conservative management, physical therapy, and bilateral clitoral artery embolization. We performed bilateral pudendal nerve blocks with Kenalog and Bupivacaine, which provided almost complete relief for 2-3 months. We performed a bilateral pudendal nerve radiofrequency ablation; however, there was minimal benefit. RW continues to have significant relief with serial pudendal nerve blocks.

Summary and conclusion: Persistent genital arousal disorder is often refractory to medication and physical therapy requiring significant intervention such as entrapment surgery or artery embolization. Our case demonstrates pudendal nerve blocks as a potential treatment modality with minimal side effects.

背景:持续性生殖器唤起障碍(PGAD)是一种病症,其特点是在没有刺激的情况下,生殖器会出现不想要的、潜在的疼痛感或自发的性高潮。我们介绍了一例患有难治性生殖器唤起障碍的 55 岁女性病例,她接受了连续的阴部神经阻滞治疗:RW 是一名 55 岁的女性,患有慢性盆腔痛、阴部神经痛、多发性抑郁症、SI、GAD、CRPS 和持续性生殖器唤起障碍 11 年。她的 PGAD 对保守治疗、物理治疗和双侧阴蒂动脉栓塞术均无效。我们用 Kenalog 和布比卡因对她进行了双侧阴股神经阻滞,结果在 2-3 个月内几乎完全缓解了她的症状。我们进行了双侧阴部神经射频消融术,但效果甚微。通过连续的阴部神经阻滞治疗,RW的症状继续得到明显缓解:持续性生殖器唤醒障碍通常对药物和物理治疗无效,需要进行重大干预,如夹层手术或动脉栓塞。我们的病例表明,阴部神经阻滞是一种潜在的治疗方式,而且副作用极小。
{"title":"Pudendal nerve blockade for persistent genital arousal disorder (PGAD): A clinical review and case report.","authors":"Michael J Gyorfi, Alaa Abd-Elsayed","doi":"10.1111/papr.13362","DOIUrl":"10.1111/papr.13362","url":null,"abstract":"<p><strong>Background: </strong>Persistent genital arousal disorder (PGAD) is a condition characterized by unwanted and potentially painful genital sensations or spontaneous orgasms without stimulation. We present a case of a 55-year-old woman with refractory genital arousal disorder that was treated with serial pudendal nerve blocks.</p><p><strong>Case: </strong>RW is a 55-year-old woman with chronic pelvic pain, pudendal neuralgia, MDD, SI, GAD, CRPS, and persistent genital arousal disorder for 11 years. Her PGAD was refractory to conservative management, physical therapy, and bilateral clitoral artery embolization. We performed bilateral pudendal nerve blocks with Kenalog and Bupivacaine, which provided almost complete relief for 2-3 months. We performed a bilateral pudendal nerve radiofrequency ablation; however, there was minimal benefit. RW continues to have significant relief with serial pudendal nerve blocks.</p><p><strong>Summary and conclusion: </strong>Persistent genital arousal disorder is often refractory to medication and physical therapy requiring significant intervention such as entrapment surgery or artery embolization. Our case demonstrates pudendal nerve blocks as a potential treatment modality with minimal side effects.</p>","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":" ","pages":"852-855"},"PeriodicalIF":2.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140094419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical outcomes of spinal cord stimulation in patients with intractable leg pain in Japan. 日本顽固性腿痛患者脊髓刺激的临床疗效。
IF 2.5 3区 医学 Q2 ANESTHESIOLOGY Pub Date : 2024-07-01 Epub Date: 2024-03-08 DOI: 10.1111/papr.13363
Keisuke Ueno, Koichi Tachibana, Nobutaka Masunaga, Yukinori Shinoda, Tomoko Minamisaka, Hirooki Inui, Ryohei Amiya, Soki Inoue, Arisa Murakami, Shiro Hoshida

Background: Neuromodulation through spinal cord stimulation (SCS) is a therapeutic option for relieving leg pain and improving the chances of limb salvage in patients with intractable chronic limb-threatening ischemia (CLTI); however, there is no consensus on its indications.

Objective: The aim of this study was to assess the clinical outcomes of SCS in patients with intractable leg pain caused by various diseases treated in the department of cardiovascular medicine in Japan.

Methods: This was a retrospective study of patients who underwent SCS for pain management. Patients were considered eligible for the therapy if they met the following criteria: (1) intractable leg pain (numerical rating scale [NRS] score of 10), (2) no revascularization option, and (3) no septicemia.

Results: Twenty patients (mean age: 77 years; men/women: 11/9) were included in this study. The NRS score of the patients significantly reduced from 10 ± 0 before procedure to 4 ± 3 at discharge (p < 0.001). The clinical response rate of the entire cohort was 65% (13/20) at 17 ± 14 months after implantation; however, patients with intractable CLTI showed a low response rate (45%), whereas those with subacute limb ischemia showed a high response rate (100%). A multivariable regression analysis showed that hemoglobin level was significantly associated with treatment response, even after adjusting for age and sex (p = 0.026). The area under the receiver operating characteristic curve for the correlation between hemoglobin level (cutoff, 11.4 g/dL) and clinical response to SCS was 0.824 (0.619-1).

Conclusions: SCS can reduce clinical symptoms in majority of patients with intractable leg pain. Although implantation of an SCS device has been shown to improve microvascular perfusion insufficiency, the correlation between hemoglobin level and the clinical effect of SCS indicates that a preserved microcirculatory vascular bed is essential for the therapy to be effective.

背景:通过脊髓刺激(SCS)进行神经调控是一种治疗方法,可缓解顽固性慢性肢体缺血(CLTI)患者的腿部疼痛并提高肢体挽救的机会;然而,关于其适应症尚未达成共识:本研究旨在评估在日本心血管内科接受治疗的各种疾病引起的顽固性腿痛患者接受 SCS 治疗的临床效果:这是一项回顾性研究,研究对象是接受 SCS 治疗的疼痛患者。符合以下条件的患者均可接受治疗:(结果:20 名患者(平均年龄:77 岁)接受了 SCS 治疗:本研究共纳入 20 名患者(平均年龄:77 岁;男性/女性:11/9)。患者的 NRS 评分从术前的 10 ± 0 显著降至出院时的 4 ± 3(p 结论:SCS 可以减轻大部分患者的临床症状:SCS 可以减轻大多数顽固性腿痛患者的临床症状。虽然植入 SCS 装置已被证明能改善微血管灌注不足,但血红蛋白水平与 SCS 临床效果之间的相关性表明,保留微循环血管床对治疗效果至关重要。
{"title":"Clinical outcomes of spinal cord stimulation in patients with intractable leg pain in Japan.","authors":"Keisuke Ueno, Koichi Tachibana, Nobutaka Masunaga, Yukinori Shinoda, Tomoko Minamisaka, Hirooki Inui, Ryohei Amiya, Soki Inoue, Arisa Murakami, Shiro Hoshida","doi":"10.1111/papr.13363","DOIUrl":"10.1111/papr.13363","url":null,"abstract":"<p><strong>Background: </strong>Neuromodulation through spinal cord stimulation (SCS) is a therapeutic option for relieving leg pain and improving the chances of limb salvage in patients with intractable chronic limb-threatening ischemia (CLTI); however, there is no consensus on its indications.</p><p><strong>Objective: </strong>The aim of this study was to assess the clinical outcomes of SCS in patients with intractable leg pain caused by various diseases treated in the department of cardiovascular medicine in Japan.</p><p><strong>Methods: </strong>This was a retrospective study of patients who underwent SCS for pain management. Patients were considered eligible for the therapy if they met the following criteria: (1) intractable leg pain (numerical rating scale [NRS] score of 10), (2) no revascularization option, and (3) no septicemia.</p><p><strong>Results: </strong>Twenty patients (mean age: 77 years; men/women: 11/9) were included in this study. The NRS score of the patients significantly reduced from 10 ± 0 before procedure to 4 ± 3 at discharge (p < 0.001). The clinical response rate of the entire cohort was 65% (13/20) at 17 ± 14 months after implantation; however, patients with intractable CLTI showed a low response rate (45%), whereas those with subacute limb ischemia showed a high response rate (100%). A multivariable regression analysis showed that hemoglobin level was significantly associated with treatment response, even after adjusting for age and sex (p = 0.026). The area under the receiver operating characteristic curve for the correlation between hemoglobin level (cutoff, 11.4 g/dL) and clinical response to SCS was 0.824 (0.619-1).</p><p><strong>Conclusions: </strong>SCS can reduce clinical symptoms in majority of patients with intractable leg pain. Although implantation of an SCS device has been shown to improve microvascular perfusion insufficiency, the correlation between hemoglobin level and the clinical effect of SCS indicates that a preserved microcirculatory vascular bed is essential for the therapy to be effective.</p>","PeriodicalId":19974,"journal":{"name":"Pain Practice","volume":" ","pages":"826-831"},"PeriodicalIF":2.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140065666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Pain Practice
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1